

The International Polycystic Kidney Disease Consortium. 1995. Polycystic kidney disease: The complete structure of the PKD1 gene and its protein. *Cell* 81:289-298.

Wheatley, D.N. 1995, *Pathobiology* 63:222-238.

Whitehead et al., 1999, *Exp. Eye Res.* 69:491-503.

Yoder et al., 1996, *Kid. Int.* 50:1240-1248.

## WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule selected from the group consisting of:

a) a nucleic acid molecule having a nucleotide sequence which is at least 90% identical to the nucleotide sequence of Chlamydomonas intraflagellar transport (IFT) particle protein gene 20, 27, 46, 52, 57, 72, 88, 122, 139, or Che-2, or a complement thereof;

b) a nucleic acid molecule comprising at least 15 nucleotide residues and having a nucleotide sequence identical to at least 15 consecutive nucleotide residues of the nucleotide sequence of Chlamydomonas IFT particle protein gene 20, 27, 46, 52, 57, 72, 88, 122, or 139, or Che-2, or a complement thereof;

c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of Chlamydomonas IFT particle protein 20, 27, 46, 52, 57, 72, 88, 122, 139, or Che-2; or

d) a nucleic acid molecule which encodes a polypeptide comprising at least 10 amino acids and having an amino acid sequence identical to at least 10 consecutive amino acids of the amino acid sequence of Chlamydomonas IFT particle protein 20, 27, 46, 52, 57, 72, 88, 122, 139, or Che-2.

2. The isolated nucleic acid molecule of claim 1, which is selected from the group consisting of:

a) a nucleic acid having the nucleotide sequence of Chlamydomonas IFT particle protein gene 20, 27, 46, 52, 57, 72, 88, 122, 139, or Che-2, or a complement thereof; and

b) a nucleic acid molecule which encodes a polypeptide having the amino acid sequence of Chlamydomonas IFT particle protein 20, 27, 46, 52, 57, 72, 88, 122, 139, or Che-2.

3. The nucleic acid molecule of claim 1, further comprising nucleic acid sequences encoding a heterologous polypeptide.

- 27
- 28 4. A vector comprising the nucleic acid molecule of claim 1.
- 29
- 30 5. A host cell comprising the nucleic acid molecule of claim 1.
- 31
- 32 6. The host cell of claim 5, wherein the host cell is a non-human mammalian host cell.
- 33
- 34 7. An isolated polypeptide selected from the group consisting of:
- 35 a) a polypeptide comprising at least 10 amino acids and having an amino acid sequence
- 36 identical to at least 10 consecutive amino acids of the amino acid sequence of *Chlamydomonas*
- 37 *intraflagellar transport* (IFT) particle protein 20, 27, 46, 52, 57, 72, 88, 122, 139, or Che-2;
- 38 b) a polypeptide comprising the amino acid sequence of *Chlamydomonas* IFT particle
- 39 protein 20, 27, 46, 52, 57, 72, 88, 122, 139, or Che-2, wherein the polypeptide comprises one or
- 40 more conservative amino acid substitutions that do not inhibit the biological activity of the
- 41 polypeptide relative to a corresponding native *Chlamydomonas* IFT particle protein; and
- 42 c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide
- 43 sequence which is at least 90% identical to a nucleic acid consisting of the nucleotide sequence
- 44 of *Chlamydomonas* IFT particle protein gene 20, 27, 46, 52, 57, 72, 88, 122, 139, or Che-2, or a
- 45 complement thereof.
- 46
- 47 8. The isolated polypeptide of claim 7, comprising the amino acid sequence of
- 48 *Chlamydomonas* IFT particle protein 20, 27, 46, 52, 57, 72, 88, 122, 139, or Che-2.
- 49
- 50 9. The polypeptide of claim 7, wherein the polypeptide further comprises heterologous
- 51 amino acid residues.
- 52
- 53 10. An antibody that selectively binds to the polypeptide of claim 7.
- 54
- 55 11. An antibody that selectively binds to the polypeptide of claim 8.
- 56
- 57 12. An isolated nucleic acid molecule selected from the group consisting of:

a) a nucleic acid molecule having a nucleotide sequence which is at least 90% identical to the nucleotide sequence of mouse intraflagellar transport (IFT) particle protein gene 57, or a complement thereof;

b) a nucleic acid molecule comprising at least 15 nucleotide residues and having a nucleotide sequence identical to at least 15 consecutive nucleotide residues of the nucleotide sequence of mouse IFT particle protein gene 57, or a complement thereof;

c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of mouse IFT particle protein 57; or

d) a nucleic acid molecule which encodes a polypeptide comprising at least 10 amino acids and having an amino acid sequence identical to at least 10 consecutive amino acids of the amino acid sequence of mouse IFT particle protein 57.

13. The isolated nucleic acid molecule of claim 12, which is selected from the group consisting of:

a) a nucleic acid having the nucleotide sequence of mouse IFT particle protein gene 57 or a complement thereof; and

b) a nucleic acid molecule which encodes a polypeptide having the amino acid sequence of mouse IFT particle protein 57.

14. An isolated polypeptide selected from the group consisting of:

a) a polypeptide comprising at least 10 amino acids and having an amino acid sequence identical to at least 10 consecutive amino acids of the amino acid sequence of mouse intraflagellar transport (IFT) particle protein 57;

b) a polypeptide comprising the amino acid sequence of mouse IFT particle protein 57, wherein the polypeptide comprises one or more conservative amino acid substitutions that do not inhibit the biological activity of the polypeptide relative to native mouse IFT particle protein 57; and

c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to a nucleic acid consisting of the nucleotide sequence of mouse IFT particle protein gene 57, or a complement thereof.

15. The isolated polypeptide of claim 14, comprising the amino acid sequence of mouse IFT particle protein 57.

16. A method for identifying a candidate compound that modulates the activity of mouse intraflagellar transport (IFT) particle protein 57, the method comprising:

contacting a test compound to an isolated IFT particle polypeptide of claim 14; and  
determining whether the test compound interacts with the polypeptide, wherein interaction indicates that the test compound is a candidate modulator of mouse IFT particle protein 57.

17. A method for identifying a candidate compound that modulates the activity of a human intraflagellar transport (IFT) particle protein, the method comprising:

contacting a test compound to an isolated IFT particle polypeptide; and  
determining whether the test compound interacts with the polypeptide, wherein interaction indicates that the test compound is a candidate modulator of a human IFT particle protein.

18. The method of claim 17, wherein the isolated human IFT particle polypeptide is selected from the group consisting of human IFT particle polypeptide 20-1, 20-2, 20-3, 27, 46, 52, 57-1, 57-2, 72, 88, 122, 139-1, 139-2 and Che-2.

19. The method of claim 17, wherein the test compound binds to the isolated IFT particle polypeptide and wherein the modulation is inhibition of activity.

20. The method of claim 17, wherein the test compound binds to the isolated IFT particle polypeptide and wherein the modulation is increasing activity.

21. The method of claim 17, further comprising  
contacting the candidate modulator to a culture of cells comprising functional cilia, and  
determining whether the candidate modulator inhibits cilia function, wherein inhibition of cilia function indicates the candidate modulator is an IFT particle protein inhibitory agent.

120  
 121 22. The method of claim 17, further comprising  
 122 contacting the candidate modulator to a culture of cells comprising non-functional cilia  
 123 and lacking a specific IFT particle protein, and  
 124 determining whether the candidate modulator restores cilia function, wherein restoration  
 125 of cilia function indicates the candidate modulator is an IFT particle protein restorative agent.  
 126

127 23. A method for identifying a candidate compound that restores the activity of a  
 128 defective or absent human intraflagellar transport (IFT) particle protein, the method comprising:  
 129 obtaining a mixture of isolated IFT particle polypeptides that comprises (i) all but one of  
 130 the IFT particle polypeptides required to form the IFT particle, and (ii) a medium that enables the  
 131 IFT particle polypeptides to form the IFT particle when all normal IFT particle polypeptides that  
 132 constitute that IFT particle are present;  
 133 contacting a test compound to the mixture; and  
 134 determining whether the test compound enables the IFT particle to be formed, wherein  
 135 IFT particle formation indicates the test compound is a candidate compound that restores the  
 136 activity of a defective or absent human IFT particle protein.  
 137

138 24. The method of claim 23, further comprising  
 139 contacting the candidate compound to a culture of cells comprising non-functional cilia  
 140 and lacking a specific IFT particle protein, and  
 141 determining whether the candidate compound restores cilia function, wherein restoration  
 142 of cilia function indicates the candidate compound is an IFT particle protein restorative agent.  
 143

144 25. The method of claim 23, wherein the human IFT particle polypeptide is selected  
 145 from the group consisting of human IFT particle polypeptides 20-1, 20-2, 20-3, 27, 46, 52, 57-1,  
 146 57-2, 72, 88, 122, 139-1, 139-2 and Che-2.  
 147

148 26. A method of diagnosing a disorder in a tissue in a subject caused by a defective or  
 149 absent human intraflagellar transport (IFT) particle protein, the method comprising  
 150 obtaining a sample of cells from the tissue;

151 disrupting the cells;  
152 contacting the disrupted cell sample with an antibody that specifically binds to a normal  
153 human IFT particle protein; and  
154 detecting binding of the antibody to any IFT particle protein in the sample, wherein  
155 absence of binding indicates that the tissue has a disorder caused by a defective or absent IFT  
156 particle protein.

157  
158 27. The method of claim 26, wherein the disorder is kidney disease, retinal disorder,  
159 thyroid disorder, chondrocyte disease, olfactory disease, azoospermia, or primary ciliary  
160 dyskinesia.

161  
162 28. A method of treating a disorder in a subject caused by a defective or absent  
163 intraflagellar transport (IFT) protein, the method comprising administering to the subject a  
164 human IFT particle polypeptide in an amount effective to restore the function of the defective or  
165 absent IFT particle protein.

166  
167 29. The method of claim 28, wherein administering the human IFT particle polypeptide  
168 comprises administering a nucleic acid that encodes a human IFT particle polypeptide.

169  
170 30. The method of claim 28, wherein the human IFT particle polypeptide is selected  
171 from the group consisting of human IFT particle polypeptides 20-1, 20-2, 20-3, 27, 46, 52, 57-1,  
172 57-2, 72, 88, 122, 139-1, 139-2 and Che-2.

173  
174 31. A method of treating an infection in a subject caused by a pathogen that comprises a  
175 intraflagellar transport (IFT) particle protein, the method comprising administering to the subject  
176 an effective amount of an agent that inhibits the function of the IFT particle protein.

177  
178 32. The method of claim 31, wherein the agent is an antibody that binds specifically to  
179 the IFT particle protein.

180  
181 33. The method of claim 31, wherein the subject is a mammal.

182

183

34. The method of claim 31, wherein the subject is a human.

184

185

35. The method of claim 31, wherein the subject is a plant.

186

187

36. The method of claim 31, wherein the pathogen is a nematode, insect, protozoa  
bacteria.

188

189